NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. - Lee, Eudocia Q.; Zhang, Peixin; Wen, Patrick Y.; Gerstner, Elizabeth R.; Reardon, David A.; Aldape, Kenneth D.; deGroot, John F.; Pan, Edward; Raizer, Jeffrey J.; Kim, Lyndon J.; Chmura, Steven J.; Robins, H. Ian; et al. (Cancer (0008543X), 2020)